One of the most significant scientific achievements of recent years is the recommendation of researchers from the University of Debrecen in one of the world's leading oncology journals, Nature Reviews Clinical Oncology. Based on their research results, the colleagues of the Department of Biophysics and Cell Biology, Faculty of Medicine have formulated a recommendation to clinicians on the composition of cell therapy products to be used in organ tumors for more successful treatments.
The January issue of Nature Reviews Clinical Oncology published a summary paper summarising perspectives on the use of chimeric antigen receptor gene-edited immune cell therapies for organ tumors (so-called solid tumors). The paper is co-authored by Steven M. Albelda, Principal Investigator, Center for Immune Cell Therapy, University of Pennsylvania. The article refers to a finding published in August 2021 by researchers at the Institute of Biophysics and Cell Biology at the University of Debrecen's Faculty of General Medicine, which provides recommendations to clinicians on the composition of cell therapy formulations to use for better treatment outcomes.
A cikk folytatása itt olvasható.